This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-22 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
== Further reading == Degarmo, E. Paul; Black, J T.; Kohser, Ronald A. (2003), Materials and Processes in Manufacturing (9th ed.), Wiley, ISBN 0-471-65653-4. Kalpakjian, Serope; Schmid, Steven R. (2006), Manufacturing Engineering and Technology (5th ed.), Upper Saddle River, NJ: Pearson Prentice Hall, ISBN 0-13-148965-8
Pottery – many indigenous American cultures and peoples independently invented and then refined pottery in the Americas into fine works of art, as well for utilitarian usage. The Moche and Maya were some of the best potters from the ancient Americas, and their work still inspires awe amongst us for the level of artistry, creativity, and sophistication, which such highly prized works of arts involved. The Navajo are also very skilled developers of pottery and their works in the present time are highly detailed and much prized. Many other indigenous American cultures also developed their own pottery styles during the pre-Columbian time periods and continued to refine their artwork into the modern era. Pumpkins – indigenous Americans were the first to domesticate and grow pumpkins. Puna ibis - the Puna ibis was domesticated by the Uru people. Puquios Pyramids – advanced civilizations in Mexico, such as the Toltecs, Olmecs, Zapotecs, Aztecs, Mayans, Mixtecs, developed their own myriad styles of pyramids, usually step pyramid, which served for ceremonial/religious and administrative functions. In Mesoamerica, the largest pyramid in the world—The Great Pyramid of Cholula—began to be constructed by the inhabitants of Cholula in the 3rd century BCE. In the Andean regions, the Moches, and some ancient Peruvians also constructed gigantic pyramids as well without any influence from Old World civilizations.
== Origins == In 1927, Sakel, who had recently qualified as a medical doctor in Vienna and was working in a psychiatric clinic in Berlin, began to use low (sub-coma) doses of insulin to treat drug addicts and psychotics, and when one of the patients experienced improved mental clarity after having slipped into an accidental coma, Sakel reasoned the treatment might work for mentally ill patients. Having returned to Vienna, he treated schizophrenic patients with larger doses of insulin in order to deliberately produce coma and sometimes convulsions. Sakel made his results public in 1933, and his methods were soon taken up by other psychiatrists. Joseph Wortis, after seeing Sakel practice it in 1935, introduced it to the US. British psychiatrists from the Board of Control visited Vienna in 1935 and 1936, and by 1938, 31 hospitals in England and Wales had insulin treatment units. In 1936, Sakel moved to New York and promoted the use of insulin coma treatment in US psychiatric hospitals. By the late 1940s, the majority of psychiatric hospitals in the US were using insulin coma treatment.
Sources: en.wikipedia.org
ZMapp was first used during the 2014 West Africa Ebola Virus outbreak, having not previously undergone any human clinical trials to determine its efficacy or potential risks. By October 2014, the United States Food and Drug Administration had approved the use of several experimental drugs, including ZMapp, to be used on patients infected with Ebola virus. The use of such drugs during the epidemic was also deemed ethical by the World Health Organization (WHO). In 2014, a limited supply of ZMapp was used to treat 7 individuals infected with the Ebola virus; of these 2 died. The outcome is not considered to be statistically significant. Mapp announced in August 2014, that supplies of ZMapp had been exhausted.
Vacuum deaerator Composite plastic moulding processes; Production of most types of electric lamps, vacuum tubes, and CRTs where the device is either left evacuated or re-filled with a specific gas or gas mixture; Semiconductor processing, notably ion implantation, dry etch and PVD, ALD, PECVD and CVD deposition and so on in photolithography; Electron microscopy; Medical processes that require suction; Uranium enrichment; Medical applications such as radiotherapy, radiosurgery and radiopharmacy; Analytical instrumentation to analyse gas, liquid, solid, surface and bio materials; Mass spectrometers to create a high vacuum between the ion source and the detector; Vacuum coating on glass, metal and plastics for decoration, for durability and for energy saving, such as low-emissivity glass, hard coating for engine components (as in Formula One), ophthalmic coating, milking machines and other equipment in dairy sheds; Vacuum impregnation of porous products such as wood or electric motor windings; Air conditioning service (removing all contaminants from the system before charging with refrigerant); Trash compactor; Vacuum engineering; Sewage systems (see EN1091:1997 standards); Freeze drying; and Fusion research. In the field of oil regeneration and re-refining, vacuum pumps create a low vacuum for oil dehydration and a high vacuum for oil purification. A vacuum may be used to power, or provide assistance to mechanical devices. In hybrid and diesel engine motor vehicles, a pump fitted on the engine (usually on the camshaft) is used to produce a vacuum.
This activity was used to determine and isolate cell-permeable inhibitors of PTPs that could be used as potential drugs later on, for example, working on CD45 and Bacillus anthracis. Related to this work on PTPs, in 2006, Barrios and Sayantan Mitra filed a patent for "Coumarin-based amino acids for used in enzyme activity and substrate specificity assay" which can be incorporated into peptides to visualize the hydrolyzation of PTPs. Additionally, in 2009, Barrios, Mitra, Stephanie Stanford, and Nunzio Bottini filed a patent for a "Method for monitoring intracellular tyrosine phosphatase activity". This invention was based on the CD45 probe used in the previously mentioned tyrosine phosphatases and is used to monitor "intracellular tyrosine dephosphorylation at the single-cell level" and the potential development of novel therapeutics. As assistant professor of Medicinal Chemistry at the University of Utah in 2012, Barrios worked on a drug to target a parasite known as Entamoeba histolytica. This parasite causes amebiasis which was the fourth leading cause of death world-wide caused by protozoan infections. Metronidazole, the drug that was being used at the time, had adverse side effects and some resistance to the medication was on the rise. Barrios contributed to the development of a new anti-parasitic drug. Through a high-throughput drug screen, they found that auranofin, which is commonly used for rheumatoid arthritis, targets TrxR which decreases the parasite's ability to withstand oxidative stress.
It has little arable land and few natural resources, importing most of its food and raw materials. More than 90% of Hong Kong's food is imported, including nearly all of its meat and rice. Agricultural activity is 0.1% of GDP and consists of growing premium food and flower varieties. Although the territory had one of Asia's largest manufacturing economies during the latter half of the colonial era, Hong Kong's economy is now dominated by the service sector. The sector generates 92.7% of economic output, with the public sector accounting for about 10%. Between 1961 and 1997, Hong Kong's gross domestic product increased by a factor of 180, and per capita GDP increased by a factor of 87. The territory's GDP relative to mainland China's peaked at 27% in 1993; it fell to less than 3% in 2017, as the mainland developed and liberalised its economy. Economic and infrastructure integration with China has increased significantly since the 1978 start of the reform and opening up on the mainland. Since resumption of cross-boundary train service in 1979, many rail and road links have been improved and constructed, facilitating trade between regions. The Closer Economic Partnership Arrangement formalised a policy of free trade between the two areas, with each jurisdiction pledging to remove remaining obstacles to trade and cross-boundary investment. A similar economic partnership with Macau details the liberalisation of trade between the special administrative regions. Chinese companies have expanded their economic presence in the territory since the handover.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.